Brian Dean

List of Publications by Year in Descending Order

302 papers	11,972 citations	57 h-index	98 g-index
332 ext. papers	13,346 ext. citations	5.2 avg, IF	6.37 L-index

#	Paper	IF	Citations
302	SMAD4 protein is decreased in the dorsolateral prefrontal and anterior cingulate cortices in schizophrenia. *World Journal of Biological Psychiatry*, **2021**, 22, 70-77	3.8	0
301	Cortical expression of the RAPGEF1 gene in schizophrenia: investigating regional differences and suicide. *Psychiatry Research*, **2021**, 298, 113818	9.9	0
300	The impact of ovariectomy and chronic estrogen treatment on gene expression in the rat cortex: Implications for psychiatric disorders. *Psychoneuroendocrinology*, **2021**, 127, 105192	5	2
299	An investigation into nicotinic receptor involvement in mood disorders uncovers novel depression candidate genes. *Journal of Affective Disorders*, **2021**, 288, 154-160	6.6	0
298	Lipid Pathology of the Corpus Callosum in Schizophrenia and the Potential Role of Abnormal Gene Regulatory Networks with Reduced Microglial Marker Expression. *Cerebral Cortex*, **2021**, 31, 448-462	5.1	5
297	Changes in cortical gene expression in major depressive disorders: More evidence implicating inflammatory-related pathways in disease etiology **2021**, 89-100		0
296	Abnormal gene expression of BDNF, but not BDNF-AS, in iPSC, neural stem cells and postmortem brain samples from bipolar disorder. *Journal of Affective Disorders*, **2021**, 290, 61-64	6.6	1
295	Lower levels of tubulin alpha 1b in the frontal pole in schizophrenia supports a role for changed cytoskeletal dynamics in the aetiology of the disorder. *Psychiatry Research*, **2021**, 303, 114096	9.9	0
294	Changes in cortical gene expression in the muscarinic M1 receptor knockout mouse: potential relevance to schizophrenia, Alzheimer's disease and cognition. *NPJ Schizophrenia*, **2021**, 7, 44	5.5	0
293	PET Imaging of brain muscarinic receptors with F-Fluorobenzyl-Dexetimide: A first in human study. *Psychiatry Research - Neuroimaging*, **2021**, 316, 111354	2.9	2
292	Higher levels of α7 nicotinic receptors, but not choline acetyltransferase, in the dorsolateral prefrontal cortex from a sub-group of patients with schizophrenia. *Schizophrenia Research*, **2020**, 222, 283-290	3.6	1
291	Excitatory amino acid transporter (EAAT)1 and EAAT2 mRNA levels are altered in the prefrontal cortex of subjects with schizophrenia. *Journal of Psychiatric Research*, **2020**, 123, 151-158	5.2	6
290	The Impact of Removal of Ovarian Hormones on Cholinergic Muscarinic Receptors: Examining Prepulse Inhibition and Receptor Binding. *Brain Sciences*, **2020**, 10,	3.4	1
289	Associations between catechol-O-methyltransferase (COMT) genotypes at rs4818 and rs4680 and gene expression in human dorsolateral prefrontal cortex. *Experimental Brain Research*, **2020**, 238, 477-486	2.3	6
288	Evidence for Altered Metabolism of Sphingosine-1-Phosphate in the Corpus Callosum of Patients with Schizophrenia. *Schizophrenia Bulletin*, **2020**,	1.3	5
287	The influence of COMT rs4680 on functional connectivity in healthy adults: A systematic review. *European Journal of Neuroscience*, **2020**, 52, 3851-3878	3.5	2
286	Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia. *Psychiatry Research*, **2020**, 288, 112989	9.9	9

285	Cell Type-Specific Methylome-wide Association Studies Implicate Neurotrophin and Innate Immune Signaling in Major Depressive Disorder. *Biological Psychiatry*, **2020**, 87, 431-442	7.9	21
284	S176. A PRELIMINARY INVESTIGATION OF COMT GENE INVOLVEMENT IN COGNITIVE FLEXIBILITY AND ATTENTION IN SCHIZOPHRENIA SPECTRUM DISORDERS. *Schizophrenia Bulletin*, **2020**, 46, S104-S105	7.3	78
283	Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?. *Non-coding RNA*, **2020**, 6,	7.1	3
282	Methylome-wide association findings for major depressive disorder overlap in blood and brain and replicate in independent brain samples. *Molecular Psychiatry*, **2020**, 25, 1344-1354	15.1	28
281	mRNA expression of the P5 ATPase ATP13A4 is increased in Broca area from subjects with schizophrenia. *World Journal of Biological Psychiatry*, **2020**, 21, 402-408	3.8	5
280	Changes in cortical protein markers of iron transport with gender, major depressive disorder and suicide. *World Journal of Biological Psychiatry*, **2020**, 21, 119-126	3.8	8
279	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. *World Journal of Biological Psychiatry*, **2020**, 21, 775-783	3.8	15
278	F35. GENE EXPRESSION SUGGEST ALTERED GLUTAMATERGIC, DOPAMINERGIC AND ESTROGEN CLASSICAL PATHWAYS IN WORKING MEMORY DEFICIT IN SCHIZOPHRENIA. *Schizophrenia Bulletin*, **2019**, 45, S268-S269	1.3	78
277	Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia. *International Journal of Neuropsychopharmacology*, **2019**, 22, 640-650	5.8	6
276	Changed cortical risk gene expression in major depression and shared changes in cortical gene expression between major depression and bipolar disorders. *Australian and New Zealand Journal of Psychiatry*, **2019**, 53, 1189-1198	2.6	8
275	Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology. *EMBO Molecular Medicine*, **2019**, 11, e10695	12	25
274	Tumor necrosis factor receptor□2: A potential target for antidepressant drug development. *Clinical and Experimental Neuroimmunology*, **2019**, 10, 272-282	0.4	
273	Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia. *NPJ Schizophrenia*, **2019**, 5, 20	5.5	8
272	Cortical biometals: Changed levels in suicide and with mood disorders. *Journal of Affective Disorders*, **2019**, 243, 539-544	6.6	3
271	□actin does not show the characteristics of a reference protein in human cortex. *Electrophoresis*, **2019**, 40, 247-253	3.6	4
270	Changes in levels of cortical metabotropic glutamate 2 receptors with gender and suicide but not psychiatric diagnoses. *Journal of Affective Disorders*, **2019**, 244, 80-84	6.6	6
269	Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. *NPJ Schizophrenia*, **2018**, 4, 4	5.5	22
268	Epigenetic Aging in Major Depressive Disorder. *American Journal of Psychiatry*, **2018**, 175, 774-782	11.9	92

267	Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor. *Molecular Psychiatry*, **2018**, 23, 295-303	15.1	31
266	Non-Coding RNA as Novel Players in the Pathophysiology of Schizophrenia. *Non-coding RNA*, **2018**, 4,	7.1	33
265	Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia. *Journal of Psychiatry and Neuroscience*, **2018**, 43, 338-346	4.5	18
264	Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disorders. *World Journal of Psychiatry*, **2018**, 8, 51-63	3	59
263	Differential effects of chronic 17β-oestradiol treatment on rat behaviours relevant to depression. *Journal of Neuroendocrinology*, **2018**, 30, e12652	3.8	12
262	Catechol-O-methyltransferase (COMT) genotypes are associated with varying soluble, but not membrane-bound COMT protein in the human prefrontal cortex. *Journal of Human Genetics*, **2018**, 63, 1251-1258	4.3	10
261	Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. *International Journal of Neuropsychopharmacology*, **2018**, 21, 216-225	5.8	6
260	Isoform specific differences in phospholipase C beta 1 expression in the prefrontal cortex in schizophrenia and suicide. *NPJ Schizophrenia*, **2017**, 3, 19	5.5	13
259	Muscarinic receptor binding changes in postmortem Parkinson's disease. *Journal of Neural Transmission*, **2017**, 124, 227-236	4.3	10
258	Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease. *Journal of Neural Transmission*, **2017**, 124, 273-284	4.3	5
257	Fatty acid composition of the postmortem corpus callosum of patients with schizophrenia, bipolar disorder, or major depressive disorder. *European Psychiatry*, **2017**, 39, 51-56	6	14
256	Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. *International Journal of Neuropsychopharmacology*, **2016**, 19,	5.8	9
255	Altered brain arginine metabolism in schizophrenia. *Translational Psychiatry*, **2016**, 6, e871	8.6	41
254	Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia. *Translational Psychiatry*, **2016**, 6, e949	8.6	25
253	The distribution of muscarinic M1 receptors in the human hippocampus. *Journal of Chemical Neuroanatomy*, **2016**, 77, 187-192	3.2	8
252	Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. *NPJ Schizophrenia*, **2016**, 2, 16002	5.5	29
251	Analysis of induced pluripotent stem cells carrying 22q11.2 deletion. *Translational Psychiatry*, **2016**, 6, e934	8.6	57
250	Validating reference genes using minimally transformed qpcr data: findings in human cortex and outcomes in schizophrenia. *BMC Psychiatry*, **2016**, 16, 154	4.2	16

249	Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. *Australian and New Zealand Journal of Psychiatry*, **2016**, 50, 275-83	2.6	28
248	Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations. *Neuropsychopharmacology*, **2016**, 41, 1620-8	8.7	18
247	Fatty acid composition and fatty acid binding protein expression in the postmortem frontal cortex of patients with schizophrenia: A case-control study. *Schizophrenia Research*, **2016**, 171, 225-32	3.6	18
246	Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue. *Translational Psychiatry*, **2016**, 6, e717	8.6	44
245	Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. *Journal of Affective Disorders*, **2016**, 190, 241-248	6.6	27
244	The Cholinergic System: An Emerging Drug Target for Schizophrenia. *Current Pharmaceutical Design* , **2016**, 22, 2124-33	3.3	29
243	Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics. *World Journal of Psychiatry*, **2016**, 6, 102-17	3	86
242	COMT genotype is associated with differential expression of muscarinic M1 receptors in human cortex. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2016**, 171, 784-9	3.5	8
241	Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank. *Schizophrenia Research*, **2016**, 177, 108-114	3.6	8
240	Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions. *Psychoneuroendocrinology*, **2016**, 74, 126-140	5	46
239	Fatty acid composition of the postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder. *Psychiatry Research*, **2015**, 227, 353-9	9.9	35
238	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank. *International Journal of Neuropsychopharmacology*, **2015**, 18, pyv042	5.8	71
237	Autophagy has a key role in the pathophysiology of schizophrenia. *Molecular Psychiatry*, **2015**, 20, 126-32	15.1	129
236	SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia. *Translational Psychiatry*, **2015**, 5, e615	8.6	16
235	The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia. *Psychiatry Research - Neuroimaging*, **2015**, 234, 182-7	2.9	11
234	A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *International Journal of Endocrinology*, **2015**, 2015, 615356	2.7	95
233	Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia. *Schizophrenia Research*, **2015**, 169, 83-88	3.6	13
232	Possible involvement of muscarinic receptors in psychiatric disorders: a focus on schizophrenia and mood disorders. *Current Molecular Medicine*, **2015**, 15, 253-64	2.5	14

231	The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?. *Current Neuropharmacology*, **2015**, 13, 739-49	7.6	26
230	Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. *International Journal of Neuropsychopharmacology*, **2014**, 17, 895-906	5.8	14
229	An investigation of the factors that regulate muscarinic receptor expression in schizophrenia. *Schizophrenia Research*, **2014**, 158, 247-54	3.6	7
228	Potential molecular and cellular mechanism of psychotropic drugs. *Clinical Psychopharmacology and Neuroscience*, **2014**, 12, 94-110	3.4	11
227	Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia. *Schizophrenia Research*, **2013**, 146, 279-84	3.6	15
226	Epigenetic mechanisms and the serotonin 2A receptor in schizophrenia. *Schizophrenia Research*, **2013**, 145, 128-9	3.6	2
225	The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2013**, 47, 7-12	5.5	11
224	Different changes in cortical tumor necrosis factor-related pathways in schizophrenia and mood disorders. *Molecular Psychiatry*, **2013**, 18, 767-73	15.1	75
223	Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. *Translational Psychiatry*, **2013**, 3, e230	8.6	46
222	Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. *International Journal of Neuropsychopharmacology*, **2013**, 16, 37-46	5.8	41
221	Cholinergic connectivity: it's implications for psychiatric disorders. *Frontiers in Cellular Neuroscience*, **2013**, 7, 55	6.1	66
220	Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. *Frontiers in Cellular Neuroscience*, **2013**, 7, 95	6.1	26
219	Neurochemistry of Schizophrenia: The Contribution of Neuroimaging Postmortem Pathology and Neurochemistry in Schizophrenia. *Current Topics in Medicinal Chemistry*, **2013**, 12, 2375-2392	3	3
218	Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathways. *Frontiers in Cellular Neuroscience*, **2013**, 7, 238	6.1	14
217	AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder. *Journal of Affective Disorders*, **2012**, 136, 1232-7	6.6	27
216	Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0879 and its metabolite in dog plasma using solid phase extraction. *Journal of Pharmaceutical and Biomedical Analysis*, **2012**, 70, 354-61	3.5	3
215	Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. *Psychiatry Research*, **2012**, 196, 201-6	9.9	27
214	The effect of riblets in rectangular duct flow. *Applied Surface Science*, **2012**, 258, 3936-3947	6.7	37

213	Muscarinic M1 receptor sequence: preliminary studies on its effects on cognition and expression. *Schizophrenia Research*, **2012**, 138, 94-8	3.6	17
212	Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study. *BMC Psychiatry*, **2012**, 12, 126	4.2	20
211	Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic association and decreased frontal cortex mRNA levels. *International Journal of Neuropsychopharmacology*, **2012**, 15, 727-37	5.8	21
210	Neurochemistry of schizophrenia: the contribution of neuroimaging postmortem pathology and neurochemistry in schizophrenia. *Current Topics in Medicinal Chemistry*, **2012**, 12, 2375-92	3	21
209	Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. *Current Pharmaceutical Biotechnology*, **2012**, 13, 1563-71	2.6	7
208	Altered neuronal markers following treatment with mood stabilizer and antipsychotic drugs indicate an increased likelihood of neurotransmitter release. *Clinical Psychopharmacology and Neuroscience*, **2012**, 10, 25-33	3.4	7
207	The neurobiology of APOE in schizophrenia and mood disorders. *Frontiers in Bioscience - Landmark*, **2011**, 16, 962-79	2.8	18
206	Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. *International Journal of Neuropsychopharmacology*, **2011**, 14, 997-1012	5.8	64
205	Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. *Neuroscience and Biobehavioral Reviews*, **2011**, 35, 804-17	9	844
204	Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. *Australian and New Zealand Journal of Psychiatry*, **2011**, 45, 140-7	2.6	27
203	Survey of the performance of commercial dose calibrators for measurement of □□I activity. *Journal of Nuclear Medicine Technology*, **2011**, 39, 302-6	1.1	9
202	Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers. *Schizophrenia Research and Treatment*, **2011**, 2011, 614730	0.6	10
201	Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. *Translational Psychiatry*, **2011**, 1, e64	8.6	97
200	Changes in Gene Expression in Subjects with Schizophrenia Associated with Disease Progression **2011**, 237-251		1
199	Low Density Lipoprotein Receptor-Related Protein and Apolipoprotein E Expression is Altered in Schizophrenia. *Frontiers in Psychiatry*, **2010**, 1, 19	5	9
198	Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. *Genome Research*, **2010**, 20, 403-12	9.7	111
197	Decreased Neuregulin 1 C-terminal fragment in Brodmann□s area 6 of patients with schizophrenia. *Schizophrenia Research*, **2010**, 124, 200-7	3.6	22
196	Decreased kainate receptors in the hippocampus of apolipoprotein D knockout mice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 271-8	5.5	5

195	Region and diagnosis-specific changes in synaptic proteins in schizophrenia and bipolar I disorder. *Psychiatry Research*, **2010**, 178, 374-80	9.9	45
194	Effects of benzodiazepine treatment on cortical GABA(A) and muscarinic receptors: studies in schizophrenia and rats. *Psychiatry Research*, **2010**, 179, 139-46	9.9	4
193	Shark-skin surfaces for fluid-drag reduction in turbulent flow: a review. *Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences*, **2010**, 368, 4775-806	3	413
192	Shark-skin surfaces for fluid-drag reduction in turbulent flow: a review. *Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences*, **2010**, 368, 5737-5737	3	16
191	Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. *Journal of Affective Disorders*, **2010**, 120, 245-8	6.6	85
190	Treating schizophrenia: novel targets for the cholinergic system. *CNS and Neurological Disorders - Drug Targets*, **2010**, 9, 241-56	2.6	18
189	Evaluation of treatment in 35 cases of bipolar suicide. *Australian and New Zealand Journal of Psychiatry*, **2009**, 43, 503-8	2.6	37
188	Role of the cholinergic system in the pathology and treatment of schizophrenia. *Expert Review of Neurotherapeutics*, **2009**, 9, 73-86	4.3	31
187	Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. *International Journal of Neuropsychopharmacology*, **2009**, 12, 45-60	5.8	98
186	Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. *Neuropsychopharmacology*, **2009**, 34, 2156-66	8.7	35
185	Abnormal hippocampal distribution of TDP-43 in patients with-late onset psychosis. *Australian and New Zealand Journal of Psychiatry*, **2009**, 43, 739-45	2.6	19
184	Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. *Journal of Affective Disorders*, **2009**, 116, 184-91	6.6	70
183	Evidence for disruption of sphingolipid metabolism in schizophrenia. *Journal of Neuroscience Research*, **2009**, 87, 278-88	4.4	70
182	Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. *Molecular Psychiatry*, **2009**, 14, 1017-23	15.1	96
181	Normal human aging and early-stage schizophrenia share common molecular profiles. *Aging Cell*, **2009**, 8, 339-42	9.9	38
180	Interpreting the significance of decreased cortical serotonin 2A receptors in schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 1583-4; author reply 1585-6	5.5	2
179	Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. *Neuroscience Letters*, **2009**, 466, 27-9	3.3	11
178	Regional and duration of illness differences in the alteration of NCAM-180 mRNA expression within the cortex of subjects with schizophrenia. *Schizophrenia Research*, **2009**, 112, 65-71	3.6	18

177	Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. *Schizophrenia Bulletin*, **2009**, 35, 973-93	1.3	177
176	Is schizophrenia the price of human central nervous system complexity?. *Australian and New Zealand Journal of Psychiatry*, **2009**, 43, 13-24	2.6	24
175	Recent advances in postmortem pathology and neurochemistry in schizophrenia. *Current Opinion in Psychiatry*, **2009**, 22, 154-60	4.9	38
174	Sensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit. *International Journal of Neuropsychopharmacology*, **2009**, 12, 917-28	5.8	10
173	Evolution of the human CNS cholineric system: has this resulted in the emergence of psychiatric disease?. *Australian and New Zealand Journal of Psychiatry*, **2009**, 43, 1016-28	2.6	2
172	Evolution of the human CNS cholineric system: has this resulted in the emergence of psychiatric disease?. *Australian and New Zealand Journal of Psychiatry*, **2009**, 43, 1016-1028	2.6	3
171	Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. *Molecular Psychiatry*, **2008**, 13, 661-72	15.1	106
170	SLC25A12 expression is associated with neurite outgrowth and is upregulated in the prefrontal cortex of autistic subjects. *Molecular Psychiatry*, **2008**, 13, 385-97	15.1	67
169	Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. *Journal of Neurochemistry*, **2008**, 107, 1188-95	6	71
168	Molecular profiles of schizophrenia in the CNS at different stages of illness. *Brain Research*, **2008**, 1239, 235-48	3.7	154
167	Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. *Schizophrenia Research*, **2008**, 99, 341-9	3.6	38
166	Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. *Schizophrenia Research*, **2008**, 104, 185-97	3.6	22
165	Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. *Schizophrenia Research*, **2008**, 106, 229-36	3.6	16
164	Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. *Psychiatry Research*, **2008**, 158, 75-8	9.9	29
163	Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 560-7	5.5	12
162	Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia. *Australian and New Zealand Journal of Psychiatry*, **2008**, 42, 740-5	2.6	12
161	Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. *International Journal of Neuropsychopharmacology*, **2008**, 11, 197-205	5.8	28
160	Role of muscarinic receptors in the activity of N-desmethylclozapine: reversal of hyperactivity in the phospholipase C knockout mouse. *Behavioural Pharmacology*, **2008**, 19, 543-7	2.4	6

159	Using differential solubilization and 2-D gel electrophoresis to visualize increased numbers of proteins in the human cortex and caudate nucleus and putamen. *Proteomics - Clinical Applications*, **2008**, 2, 1281-9	3.1	5
158	Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. *Genes, Brain and Behavior*, **2008**, 7, 266-75	3.6	263
157	CNS 14-3-3zeta: changes with sex but not psychiatric diagnoses or psychotropic drug treatment. *Schizophrenia Research*, **2007**, 93, 51-7	3.6	9
156	Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. *Biological Psychiatry*, **2007**, 61, 1161-70	7.9	76
155	Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. *Synapse*, **2007**, 61, 303-9	2.4	51
154	Towards a muscarinic hypothesis of schizophrenia. *Molecular Psychiatry*, **2007**, 12, 232-46	15.1	206
153	Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. *Brain Research*, **2007**, 1127, 108-18	3.7	128
152	Gene expression profiling in BrodmannÞ area 46 from subjects with schizophrenia. *Australian and New Zealand Journal of Psychiatry*, **2007**, 41, 308-20	2.6	64
151	Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. *Biochemical Pharmacology* , **2006**, 72, 783-93	6	34
150	Reply: Autoradiography of [3H]aspartate and Glutamate Transport in Schizophrenia. *Neuropsychopharmacology*, **2006**, 31, 687-688	8.7	1
149	Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. *Australian and New Zealand Journal of Psychiatry*, **2006**, 40, 217-24	2.6	45
148	Postmortem brain calcineurin protein levels in schizophrenia patients are not different from controls. *Schizophrenia Research*, **2006**, 83, 173-7	3.6	11
147	Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. *Schizophrenia Research*, **2006**, 88, 265-74	3.6	39
146	Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. *Human Molecular Genetics*, **2006**, 15, 1949-62	5.6	121
145	No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. *Life Sciences*, **2006**, 78, 1231-7	6.8	38
144	N-Ethylmaleimide sensitive factor in the cortex of subjects with schizophrenia and bipolar I disorder. *Neuroscience Letters*, **2006**, 391, 112-5	3.3	6
143	Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. *Psychiatry Research*, **2006**, 143, 111-20	9.9	23
142	08-02 Identifying Disease-specific Protein Expression Patterns Within the Syndrome of Schizophrenia. *Acta Neuropsychiatrica*, **2006**, 18, 331-2	3.9	

141	From Molecules to Man (CINP/ASPR Bipolar Disorder Symposium). *Acta Neuropsychiatrica*, **2006**, 18, 320	3.9	
140	Altered tripartite synapse function: is this the problem in schizophrenia and bipolar disorder?. *Acta Neuropsychiatrica*, **2006**, 18, 247-8	3.9	
139	The role of mu-opioid receptors in the pathology of schizophrenia. *Acta Neuropsychiatrica*, **2006**, 18, 300	3.9	
138	03-03 The neurobiology of bipolar disorder. *Acta Neuropsychiatrica*, **2006**, 18, 320-1	3.9	
137	09-03 The role of apolipoprotein E in the pathology of schizophrenia and bipolar disorder. *Acta Neuropsychiatrica*, **2006**, 18, 334	3.9	
136	Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. *Australian and New Zealand Journal of Psychiatry*, **2006**, 40, 217-224	2.6	5
135	Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. *Bipolar Disorders*, **2006**, 8, 133-43	3.8	84
134	Brain distribution of selected antipsychotics in schizophrenia. *Forensic Science International*, **2006**, 157, 121-30	2.6	10
133	Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder. *Molecular Brain Research*, **2005**, 138, 145-55		17
132	5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. *Neuroscience Letters*, **2005**, 379, 164-8	3.3	46
131	Cortical glutamatergic markers in schizophrenia. *Neuropsychopharmacology*, **2005**, 30, 1521-31	8.7	55
130	A family-based association study and gene expression analyses of netrin-G1 and -G2 genes in schizophrenia. *Biological Psychiatry*, **2005**, 57, 382-93	7.9	78
129	Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. *Biological Psychiatry*, **2005**, 57, 711-5	7.9	30
128	Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2005**, 371, 428-33	3.4	38
127	Understanding the Pathology of Schizophrenia: The Impact of High- Throughput Screening of the Genome and Proteome in Postmortem CNS. *Current Psychiatry Reviews*, **2005**, 1, 1-9	0.9	11
126	The endogenous cannabinoid system in schizophrenia **2004**, 127-141		1
125	M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. *Neuropsychopharmacology*, **2004**, 29, 1583-4; author reply 1585-6	8.7	12
124	The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissue. *Australian and New Zealand Journal of Psychiatry*, **2004**, 38, 135-40	2.6	14

123	Role of muscarinic receptors in the pathology of schizophrenia. *American Journal of Medical Genetics Part A*, **2004**, 126B, 8-9		
122	A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. *Thalamus & Related Systems*, **2004**, 2, 287-295		
121	Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. *Schizophrenia Research*, **2004**, 71, 383-92	3.6	23
120	GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. *Schizophrenia Research*, **2004**, 71, 377-82	3.6	54
119	Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. *Molecular Brain Research*, **2004**, 127, 128-35		27
118	Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia. *Life Sciences*, **2004**, 74, 3115-31	6.8	14
117	Identification of UGT2B9*2 and UGT2B33 isolated from female rhesus monkey liver. *Archives of Biochemistry and Biophysics*, **2004**, 426, 55-62	4.1	3
116	Glucuronidation, oxidative metabolism, and bioactivation of enterolactone in rhesus monkeys. *Archives of Biochemistry and Biophysics*, **2004**, 429, 244-51	4.1	25
115	A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. *Thalamus & Related Systems*, **2004**, 2, 287		8
114	M1 Receptor Agonism, a Possible Treatment for Cognitive Deficits in Schizophrenia. *Neuropsychopharmacology*, **2004**, 29, 1585-1586	8.7	32
113	Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. *CNS and Neurological Disorders*, **2004**, 3, 217-25		16
112	Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder. *Journal of Affective Disorders*, **2003**, 75, 65-9	6.6	17
111	Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. *Bipolar Disorders*, **2003**, 5, 257-64	3.8	97
110	The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. *Journal of Neurochemistry*, **2003**, 85, 1-13	6	80
109	Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder. *Molecular Psychiatry*, **2003**, 8, 167-75	15.1	42
108	Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow. *Pharmacogenomics Journal*, **2003**, 3, 227-34	3.5	23
107	Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. *Biological Psychiatry*, **2003**, 53, 585-92	7.9	27
106	Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype. *Biological Psychiatry*, **2003**, 54, 136-41	7.9	48

105	Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. *Biological Psychiatry*, **2003**, 54, 616-22	7.9	38
104	[3H]RX 821002 in human dorsolateral prefrontal cortex: no changes in postmortem tissue from subjects with schizophrenia. *Psychiatry Research*, **2003**, 119, 25-31	9.9	6
103	Adverse drug events: what's the truth?. *Quality and Safety in Health Care*, **2003**, 12, 165-6		13
102	Muscarinic receptors in schizophrenia. *Current Molecular Medicine*, **2003**, 3, 419-26	2.5	56
101	[(3)H]Flumazenil binding in the human hippocampal formation, frontal cortex and cerebellum detected by high-resolution phosphorimaging. *Brain Research*, **2002**, 926, 27-32	3.7	3
100	High-resolution phosphor imaging: validation for use with human brain tissue sections to determine the affinity and density of radioligand binding. *Journal of Neuroscience Methods*, **2002**, 116, 157-63	3	28
99	Decreased phorbol ester binding in the parahippocampal gyrus from subjects with schizophrenia is not associated with changes in protein kinase C. *Molecular Psychiatry*, **2002**, 7, 683-8	15.1	2
98	Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. *Molecular Psychiatry*, **2002**, 7, 886-90	15.1	46
97	Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. *Molecular Psychiatry*, **2002**, 7, 1083-91	15.1	163
96	Learning from prescribing errors. *Quality and Safety in Health Care*, **2002**, 11, 258-60		43
95	Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. *Postgraduate Medical Journal*, **2002**, 78, 142-8	2	21
94	Changes in the molecular structure of the brain in bipolar disorder: findings using human postmortem brain tissue. *World Journal of Biological Psychiatry*, **2002**, 3, 125-32	3.8	7
93	Prescribing errors in hospital inpatients: their incidence and clinical significance. *Quality and Safety in Health Care*, **2002**, 11, 340-4		268
92	Isolation and characterization of a UDP-glucuronosyltransferase (UGT1A01) cloned from female rhesus monkey. *Archives of Biochemistry and Biophysics*, **2002**, 402, 289-95	4.1	6
91	Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats. *Life Sciences*, **2002**, 70, 2699-705	6.8	3
90	The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem. *Molecular Brain Research*, **2002**, 104, 203-9		8
89	Actions of antipsychotic medications: shedding light on an enigma. *Trends in Pharmacological Sciences*, **2002**, 23, 246-247	13.2	
88	Studies in the Human Frontal Cortex: Evidence for Changes in Neurochemical Markers in Schizophrenia and Bipolar Disorder. *Neurobiological Foundation of Aberrant Behaviors*, **2002**, 93-103		

87	A proposed pathological model in the hippocampus of subjects with schizophrenia. *Clinical and Experimental Pharmacology and Physiology*, **2001**, 28, 70-3	3	24
86	A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. *Clinical and Experimental Pharmacology and Physiology*, **2001**, 28, 74-8	3	21
85	A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in BrodmannÃ Area 9 from subjects with bipolar disorder. *Journal of Affective Disorders*, **2001**, 66, 147-58	6.6	41
84	Can simulation be used to reduce errors in health care delivery? The hospital drug distribution system. *Journal of Health Services Research and Policy*, **2001**, 6, 32-7	2.4	6
83	Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 4066-71	11.5	113
82	Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of BrodmannÃ areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. *American Journal of Psychiatry*, **2001**, 158, 918-25	11.9	173
81	Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia. *Schizophrenia Research*, **2001**, 52, 107-14	3.6	21
80	Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. *Neuroscience*, **2001**, 103, 9-15	3.9	341
79	Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum. *Life Sciences*, **2001**, 69, 1257-68	6.8	15
78	Validity and reliability of observational methods for studying medication administration errors. *American Journal of Health-System Pharmacy*, **2001**, 58, 54-9	2.2	127
77	Neurochemical Changes in Postmortem Brain Tissue from Subjects with Schizophrenia: Implications for the Illness **2001**, 322-325		
76	Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia. *Molecular Psychiatry*, **2000**, 5, 85-90	15.1	78
75	Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia. *Molecular Psychiatry*, **2000**, 5, 203-7	15.1	42
74	What is a prescribing error?. *Quality in Health Care: QHC*, **2000**, 9, 232-7		262
73	Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. *American Journal of Psychiatry*, **2000**, 157, 1141-9	11.9	339
72	Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia. *Australian and New Zealand Journal of Psychiatry*, **2000**, 34, 560-9	2.6	40
71	Change in allosteric coupling between the GABA and the benzodiazepine binding sites of GABAA receptors in the planum temporale from schizophrenic subjects. *Schizophrenia Research*, **2000**, 41, 249	3.6	
70	Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. *Schizophrenia Research*, **2000**, 44, 35-45	3.6	37

69	Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. *Biological Psychiatry*, **2000**, 48, 381-8	7.9	207
68	No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. *Human Heredity*, **1999**, 49, 103-5	1.1	59
67	Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. *Journal of Neurochemistry*, **1999**, 72, 1593-9	6	134
66	A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer disease individuals. *Molecular Psychiatry*, **1999**, 4, 173-8	15.1	72
65	When should pharmacists visit their wards? An application of simulation to planning hospital pharmacy services. *Health Care Management Science*, **1999**, 2, 35-42	4	15
64	Hospital drug distribution systems in the UK and Germany--a study of medication errors. *International Journal of Clinical Pharmacy*, **1999**, 21, 25-31		64
63	Decreased hippocampal (CA3) NMDA receptors in schizophrenia. *Synapse*, **1999**, 32, 67-9	2.4	29
62	No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. *Neurochemistry International*, **1999**, 34, 109-15	4.4	41
61	The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. *Life Sciences*, **1999**, 64, 1761-71	6.8	77
60	Decreased serotonin2A receptors in Brodmann area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon?. *Molecular and Chemical Neuropathology*, **1998**, 34, 133-45		31
59	Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. *European Journal of Pharmacology*, **1998**, 349, R7-8	5.3	49
58	GABAA receptors are not altered in the auditory-linguistic association cortex of subjects with schizophrenia but are markedly decreased in the auditory cortex of rats treated with clozapine and olanzapine. *Schizophrenia Research*, **1998**, 29, 97	3.6	3
57	Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. *Australian and New Zealand Journal of Psychiatry*, **1998**, 32, 73-6	2.6	61
56	No Association between the Serotonin Transporter-Linked Promoter Region Polymorphism and Either Schizophrenia or Density of the Serotonin Transporter in Human Hippocampus. *Molecular Medicine*, **1998**, 4, 671-674	6.2	46
55	No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. *Molecular Medicine*, **1998**, 4, 671-4	6.2	9
54	5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. *Lancet, The*, **1997**, 349, 1815	40	34
53	Muscarinic M1 receptors in the caudate putamen of patients with schizophrenia: Decreased receptor density is not accompanied by decreased receptor rnRNA. *Schizophrenia Research*, **1997**, 24, 32	3.6	2
52	Diagnostic instrument for brain studies (DIBS). *Schizophrenia Research*, **1997**, 24, 34	3.6	3

51	[3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. *Neuropharmacology*, **1997**, 36, 779-86	5.5	31
50	Repeated antidepressant drug treatment, time of death and frequency of handling do not affect [3H]paroxetine binding in rat cortex. *Psychiatry Research*, **1997**, 73, 173-9	9.9	8
49	Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia. *Journal of Neural Transmission*, **1997**, 104, 1371-81	4.3	35
48	Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. *Behavioural Brain Research*, **1996**, 73, 169-75	3.4	49
47	Neither protein kinase C nor adenylate cyclase are altered in the striatum from subjects with schizophrenia. *Schizophrenia Research*, **1996**, 22, 159-64	3.6	9
46	Decreased frontal cortical serotonin2A receptors in schizophrenia. *Schizophrenia Research*, **1996**, 21, 133-9	3.6	95
45	Typical and atypical neuroleptic drugs decrease platelet 3H-dopamine uptake in the rat. *Psychiatry Research*, **1996**, 62, 259-63	9.9	1
44	Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **1996**, 20, 45-55	5.5	4
43	Treatment with haloperidol or clozapine causes changes in dopamine receptors but not adenylate cyclase or protein kinase C in the rat forebrain. *Life Sciences*, **1996**, 59, 2001-8	6.8	10
42	Problem of diagnosis in postmortem brain studies of schizophrenia. *American Journal of Psychiatry*, **1996**, 153, 533-7	11.9	106
41	Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. *Journal of Neural Transmission*, **1996**, 103, 749-57	4.3	45
40	The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. *Molecular Psychiatry*, **1996**, 1, 54-8	15.1	103
39	[3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. *Journal of Neurochemistry*, **1995**, 64, 1197-202	6	50
38	Effect of pyridoxal 5Pphosphate on the function of the purified mitochondrial tricarboxylate transport protein. *Archives of Biochemistry and Biophysics*, **1995**, 316, 215-9	4.1	9
37	The development of a method to measure [3H] dopamine uptake by washed platelets provides no evidence for circulating inhibitors of platelet dopamine uptake in schizophrenia. *Biological Psychiatry*, **1994**, 36, 595-600	7.9	6
36	Significant correlation between 14C-5-HT uptake by and 3H-paroxetine binding to platelets from healthy volunteers. *Biological Psychiatry*, **1993**, 34, 356-60	7.9	35
35	Identification of a dopamine-binding protein on the membrane of the human platelet. *Biochemical Journal*, **1992**, 287 (Pt 1), 45-50	3.8	12
34	An assay to measure the simultaneous uptake of [3H]dopamine and [14C]serotonin by the human platelet reveals an imipramine-insensitive [3H]dopamine uptake mechanism. *Life Sciences*, **1992**, 50, 341-7	6.8	8

33	Dopamine uptake by platelets from subjects with schizophrenia: a correlation with the delusional state of the patient. *Psychiatry Research*, **1992**, 41, 17-24	9.9	18
32	Inhibition of [3H]dopamine uptake by platelets by the dopamine-D2 receptor agonist RU 24926. *Journal of Pharmacy and Pharmacology*, **1991**, 43, 56-7	4.8	
31	[3H]GBR12935 Binds to Membrane from the Human Platelet **1991**, 169-170		
30	Evidence for post-translational processing of auriculin B to atriopeptin III immediately prior to secretion by hypothalamic neurons in culture. *Endocrinology*, **1990**, 127, 2598-600	4.8	10
29	Phorbol esters increase [(3)h]-dopamine uptake by human platelets. *Platelets*, **1990**, 1, 135-7	3.6	1
28	Validation of a method to measure the uptake of [3H]dopamine by human platelets. *Clinica Chimica Acta*, **1990**, 187, 37-46	6.2	5
27	A specific enhancing effect of N,N-dimethylsphingosine on epidermal growth factor receptor autophosphorylation. Demonstration of its endogenous occurrence (and the virtual absence of unsubstituted sphingosine) in human epidermoid carcinoma A431 cells.. *Journal of Biological Chemistry*, **1990**, 265, 5385-5389	5.4	91
26	Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. *Diabetes*, **1989**, 38, 779-83	0.9	93
25	Dopamine uptake by the human platelet: effects of dopamine receptor agonists. *European Journal of Pharmacology*, **1989**, 173, 165-9	5.3	11
24	Dopamine uptake by platelets is selective, temperature dependent and not influenced by the dopamine-D1 or dopamine-D2 receptor. *Life Sciences*, **1989**, 45, 401-11	6.8	24
23	Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. *Biochemistry*, **1989**, 28, 6796-800	3.2	254
22	Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. *Diabetes*, **1989**, 38, 779-783	0.9	20
21	Chromatography of serum on Sep-pak C18 corrects falsely elevated vitamin D metabolite levels measured by protein binding assay. *Clinica Chimica Acta*, **1988**, 176, 169-78	6.2	25
20	Isolation of a post-binding inhibitor of insulin action from the sera of non-insulin-dependent diabetics. *Diabetes Research*, **1987**, 5, 51-7		1
19	A high prevalence of diabetes in a rural village in Papua New Guinea. *Diabetes Research and Clinical Practice*, **1986**, 2, 97-103	7.4	9
18	Should plasma beta-endorphin be measured in patients with disorders of the hypothalamic-pituitary-adrenal axis?. *Clinical Chemistry*, **1986**, 32, 895-895	5.5	7
17	Insulin resistance, acanthosis nigricans, and polycystic ovaries associated with a circulating inhibitor of postbinding insulin action. *Journal of Clinical Endocrinology and Metabolism*, **1985**, 60, 1047-52	5.6	24
16	Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. *Diabetes*, **1985**, 34, 1306-1308	0.9	46

15	A postbinding inhibitor of insulin action. Increased concentrations in the plasma of non-insulin-dependent diabetic subjects. *Diabetes*, **1984**, 33, 450-4	0.9	9
14	Separation of free and antibody-bound insulin in plasma using a bench ultracentrifuge (Beckman Airfuge). *Clinica Chimica Acta*, **1984**, 139, 317-20	6.2	6
13	A postbinding inhibitor of insulin action. Increased concentrations in the plasma of non-insulin-dependent diabetic subjects. *Diabetes*, **1984**, 33, 450-454	0.9	6
12	Glucose tolerance and mortality in diabetes mellitus in Maltese-born residents of Victoria. *Medical Journal of Australia*, **1984**, 141, 93-7	4	10
11	Proteolysis in mitochondrial preparations and in lysosomal preparations derived from rat liver. *Archives of Biochemistry and Biophysics*, **1983**, 227, 154-63	4.1	7
10	Stability of developed colour of "BM" glucose monitoring strips. *Medical Journal of Australia*, **1983**, 1, 551-2	4	
9	Properties of Dextrostix. *Diabetes Care*, **1982**, 5, 554-5	14.6	1
8	Evaluation of home glucose measuring devices. *Medical Journal of Australia*, **1981**, 2, 197-200	4	4
7	A method for electrophoretic processing of multiple polyacrylamide gel slabs. *Analytical Biochemistry*, **1979**, 99, 105-11	3.1	5
6	Extraction and estimation of glycogen and oligosaccharides from rat heart. *Analytical Biochemistry*, **1968**, 25, 99-108	3.1	37
5	Postmortem studies of the brain cannabinoid system in schizophrenia184-192		
4	The Neurobiology of Bipolar Disorder: Findings Using Human Postmortem Central Nervous System Tissue		4
3	Confirmation of the Diagnosis of Schizophrenia after Death Using DSM-IV: A Victorian Experience		4
2	Signal Transmission, Rather Than Reception, is the Underlying Neurochemical Abnormality in Schizophrenia		6
1	Brain expressed FKBP5 delineates a therapeutic subtype of severe mental illness		1